Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017
SOUTH SAN FRANCISCO, Calif. , May 23, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced today that pivotal clinical validation data demonstrating the
View HTML
Toggle Summary Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
-- Every Major Health Plan in the U.S. Now Covers the Company's Genomic Test --
View HTML
Toggle Summary Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
-- Findings suggest that test's use reduces invasive lung-cancer diagnostic procedures by 28 percent and is cost-effective --
View HTML
Toggle Summary Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017
- New data reinforce role of Percepta® Bronchial Genomic Classifier and Envisia™ Genomic Classifier in diagnosis of difficult-to-distinguish pulmonary diseases -
View HTML
Toggle Summary Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis
Additional Data Presented on Development Of Company's Next-Generation Afirma Genomic Sequencing Classifier
View HTML
Toggle Summary Veracyte Announces Pivotal Clinical Validation Data for Next-Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis
Afirma Genomic Sequencing Classifier Combines RNA Sequencing and Machine Learning to Increase Benign Results by 30 Percent
View HTML
Toggle Summary Veracyte Announces First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif. , May 3, 2017 /PRNewswire/ -- Revenue was $16.4 Million , a 21% Growth Over Prior Year Cash Burn was $8.3 Million , a 28% Improvement Over Prior Year Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and
View HTML
Toggle Summary Veracyte Announces Multiple Studies Demonstrating Powerful Results from Afirma® Classifiers To Be Presented at the AACE 2017 Annual Meeting
Data from pivotal clinical validation study for Veracyte's next-generation Afirma Genomic Sequencing Classifier to be unveiled
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017
SOUTH SAN FRANCISCO, Calif. , April 19, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, May 3, 2017. Following the announcement, Veracyte's management will host a live conference call
View HTML
Toggle Summary Multiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis
Veracyte Also Previews Next-Generation Afirma GEC
View HTML